Crossmark

Updated evidence on cardiovascular and renal effects of GLP-1 receptor agonists and combination therapy with SGLT2 inhibitors and finerenone: a narrative review and perspectives

Crossref DOI link: https://doi.org/10.1186/s12933-024-02500-y

Published Online: 2024-11-15

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sawami, Kosuke

Tanaka, Atsushi

Node, Koichi
License Information

Text and Data Mining valid from 2024-11-15

Version of Record valid from 2024-11-15
More Information

Article History

Received: 16 July 2024

Accepted: 2 November 2024

First Online: 15 November 2024

Declarations

:

: Not applicable.

: All authors have read and approved the submission of the manuscript. The manuscript has not been published and is not being considered for publication elsewhere, in whole or in part, in any language. If the manuscript is accepted, we will approve it for publication in <i>Cardiovascular Diabetology</i>.

: KS declares nothing to disclose. AT has received honoraria from Boehringer Ingelheim Japan, Mochida, and Amgen; research funding from GlaxoSmithKline, Takeda, Bristol-Myers Squibb, and Novo Nordisk. KN has received honoraria from AstraZeneca, Bayer, Boehringer Ingelheim Japan, Daiichi Sankyo, Eli Lilly Japan, Kowa, Mitsubishi Tanabe, MSD, Novartis, Novo Nordisk, and Otsuka; research grant from Astellas, Bayer, Boehringer Ingelheim Japan, Fuji, Mochida, and Novartis; scholarship from Abbott Medical, Boehringer Ingelheim Japan, Daiichi Sankyo Healthcare, Mitsubishi Tanabe, and Teijin.

Document is current

Any future updates will be listed below